Therapy with Ursodeoxycholic Acid in Cholestatic Liver Disease

References

• Shoda M. Uber die Ursodesoxycholsäure aus Bärengallen und ihre physiologische Wirkung. J Biochem 1927; 7: 505–10
   Google Scholar
• Kanazawa T, Shimazaki A, Sato T, Hoshino T. Synthesis of ursodeoxycholic acid and its conjugated bile acid. Proc Jpn Acad 1954; 30: 391–2
   Google Scholar
• Makino I, Shinozaki K, Yoshino K, Nakagawa S. Dissolution of cholesterol gallstones by ursodeoxycholic acid. Jpn J Gastroenterol 1975; 72: 690–702
   PubMedGoogle Scholar
• Leuschner U, Leuschner M, Sieratzki J, et al. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two-year follow up: a pilot study. Dig Dis Sci 1985; 30: 642–9
   PubMedGoogle Scholar
• Poupon R, Chretien Y, Poupon R E, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis. Lancet 1987; ii: 834–6
   Google Scholar
• Poupon R E, Balkau B, Eschwége E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548–54
   PubMed Web of Science ®Google Scholar
• Stiehl L, Rudolph G, Raedsch R, Stiehl A. Effects of ursodeoxycholic acid in patients with primary sclerosing cholangitis. Bile acids as therapeutic agents, G Paumgartner, A Stiehl, W Gerok. Kluwer Academic, Dordrecht 1991; 305–7
   Google Scholar
• O'Brien C B, Senior J R, Arora-Mirchandani R, et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30 months pilot study. Hepatology 1991; 14: 838–47
   PubMed Web of Science ®Google Scholar
• Cotting J, Lentzc M J, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990; 31: 918–21
   PubMedGoogle Scholar
• Palma J, Reyes H, Ribalta J, et al. Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. Hepatology 1992; 15: 1043–7
   PubMed Web of Science ®Google Scholar
• Kallinowski B, Theilmann L, Zimmermann R, . Cyclo-sporin-induced cholestasis in heart transplanted patients may effectively be treated by ursodeoxycholic acid. Bile acids as therapeutic agents, G Paumgartner, A Stiehl, W Gerok, et al. Kluwer Academic, Dordrecht 1991; 365–6
   Google Scholar
• Svanvik J, Friman S, Persson H, . Does adjuvant ursodeoxycholic acid prevent acute rejection in liver transplant recipients?. Bile acids as therapeutic agents, G Paumgartner, A Stiehl, W Gerok, et al. Kluwer Academic, Dordrecht 1991; 357–60
   Google Scholar
• Bellantani S, Manenti T, Tiribelli C, Podda M. Ursodeoxycholic acid (UDCA) in chronic hepatitis: a double-blind multicenter clinical trial. Gastroenterology 1991; 100: A719
   PubMedGoogle Scholar
• Plevris J N, Hayes P C, Bouchier I AD. Ursodeoxycholic acid in the treatment of alcoholic liver disease. Eur J Gastroenterol Hepatol 1991; 3: 653–6
   Google Scholar
• Van Bergc Henegouwen G P, Brandt K H, Eyssen H, Parmentier G. Sulphated and unsulphated bile acids in serum, bile and urine of patients with cholestasis. Gut 1976; 17: 861–9
   PubMedGoogle Scholar
• Heuman D M, Pandak W M, Hylemon P B, Vlahcevic Z R. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991; 14: 920–6
   PubMedGoogle Scholar
• Galle P R, Theilmann R, Raedsch R, et al. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990; 12: 486–91
   PubMed Web of Science ®Google Scholar
• Heuman D M, Mills A S, McCall J, et al. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular damage caused by more hydrophobic bile salts: in vivo studies in the rat. Gastroenterology 1991; 100: 203–11
   PubMedGoogle Scholar
• Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology 1990; 98: 424–8
   PubMed Web of Science ®Google Scholar
• Yoon Y B, Hagey L R, Hofmann A F, et al. Effect of side-chain shortening on the physiological properties of bile acids: hepatic transport and effect of biliary secretion of 23-norursod-eoxycholate in rodents. Gastroenterology 1986; 90: 837–52
   PubMed Web of Science ®Google Scholar
• Crosignani A, Podda M, Battezzati P M, et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991; 14: 1000–7
   PubMed Web of Science ®Google Scholar
• Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class land class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11: 12–15
   PubMed Web of Science ®Google Scholar
• Calmus Y, Guechot J, Podevin P, et al. Differential effects of chenodeoxycholic acid and ursodeoxycholic acid on interleukin-1, interleukin-6, and tumor necrosis factor-α production by monocytes. Hepatology 1992; 16: 719–23
   PubMed Web of Science ®Google Scholar
• Yoshikawa M, Tsujii T, Matsumura K, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16: 358–64
   PubMed Web of Science ®Google Scholar
• Calmus Y, Weill B, Ozier Y, et al. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 1992; 103: 617–21
   PubMedGoogle Scholar
• Beuers U, Nathanson M H, Boyer J L. Effects of taur-oursodeoxycholate acid on cytosolic Ca2+ signals in isolated rat hepatocytes. Gastroenterology 1993; 104: 604–12
   PubMed Web of Science ®Google Scholar
• Exton J H. Role of phosphoinositides in the regulation of liver function. Hepatology 1989; 8: 152–66
   Google Scholar
• Nathanson M H, Gautam A, Bruck R, et al. Effects of Ca2+ agonists on cytosolic Ca2+ in isolated hepatocytes and on bile secretion in the isolated perfused rat liver. Hepatology 1992; 15: 107–16
   PubMedGoogle Scholar
• Wiesner R H, Grambsch P M, Lindor K D, et al. Clinical and statistical analysis of new and evolving therapies for primary biliary cirrhosis. Hepatology 1988; 8: 668–76
   PubMed Web of Science ®Google Scholar
• Wiesner R H, Ludwig J, Lindor K D, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990; 322: 1419–24
   PubMed Web of Science ®Google Scholar
• Lombard M, Portmann B, Neuberger J, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993; 104: 519–26
   PubMed Web of Science ®Google Scholar
• Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: a double-blind controlled trial. Gastroenterology 1989; 97: 1268–74
   PubMed Web of Science ®Google Scholar
• Italian Multicenter Project for UDCA treatment in PBC. Ursodeoxycholic acid (UDCA) for symptomatic primary biliary cirrhosis (PBC): a double-blind multicenter trial. J Hepatol 1989; 9: S44
   Google Scholar
• Hadziyannis S J, Hadziyannis E S, Makris A. A randomized controlled trial of UDCA in primary biliary cirrhosis. Hepatology 1989; 580: A45
   Google Scholar
• Lindor K D, Baldus W P, Jorgensen R A, et al. Ursodeoxycholic acid (UDCA) is beneficial therapy for patients with primary biliary cirrhosis (PBC). Hepatology 1992; 16: 91A
   Google Scholar
• Heathcote E JL, Cauch K, Walker V, et al. The Canadian multicentre double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1992; 16: 91A
   Google Scholar
• Raedsch R, Stiehl A, Theilmann L, et al. Influence of ursodeoxycholic acid on primary biliary cirrhosis depending on stage of the disease. Gastroenterology 1989; 96: A647
   PubMedGoogle Scholar
• Kneppelhout J C, Mulder C JJ, Van Berge Henegouwen G P, et al. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease. Neth J Med 1992; 41: 11–6
   PubMedGoogle Scholar
• Perdigoto R, Wiesner R H. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology 1992; 102: 1389–91
   PubMed Web of Science ®Google Scholar
• Shibata J, Fujiyama S, Honda Y, Sato T. Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. J Gastroenterol Hepatol 1992; 7: 277–82
   PubMed Web of Science ®Google Scholar
• Raedsch R, Stiehl A, Walker S, et al. Double-blind pilot study on the efficacy of ursodeoxycholic acid versus urso plus colchicine in primary biliary cirrhosis. Gastroenterology 1991; 100: A788
   Google Scholar
• Kaplan M M. The therapeutic effects of ursodiol and methotrexate are additive and well tolerated in primary biliary cirrhosis. Hepatology 1929; 16: 92A
   Google Scholar
• Walker S, Rudolph Raedsch G. R, Stiehl A. Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology 1992; 102: 810–5
   PubMedGoogle Scholar
• Wiesner R H, La Russo N F. Clinicopathologic features of the svndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200–6
   PubMed Web of Science ®Google Scholar
• Chapman R WG, Arborgh B AM, Rhodes J M, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography and hepatic histology. Gut 1980; 21: 870–7
   PubMed Web of Science ®Google Scholar
• Aadland E, Schrumpf E, Fausa O, et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987; 22: 655–64
   PubMed Web of Science ®Google Scholar
• Helzberg J H, Petersen J M, Boyer J L. Improved survival with primary sclerosing cholangitis. Gastroenterology 1987; 92: 1869–75
   PubMed Web of Science ®Google Scholar
• LaRusso N F, Wiesner R H, Ludwig J, et al. Prospective trial of penicillamine in primarv sclerosing cholangitis. Gastroenterology 1988; 95: 1036–42
   PubMed Web of Science ®Google Scholar
• Lebovics E, Palmer M, Woo J, Schaffner F. Outcome of primary sclerosing cholangitis. Analysis of long-term observation of 38 patients. Arch Intern Med 1987; 147: 729–31
   PubMedGoogle Scholar
• Wiesner R H, Gramsbach P, LaRusso N F, Dickson E R. Is primary sclerosing cholangitis a progressive disease or not?. Hepatology 1988; 8: 970–2
   PubMedGoogle Scholar
• Porayko M, Wiesner R H, Ludwig J, et al. Patients with asymptomatic primary sclerosing cholangitis have a progressive disease. Hepatology 1988; 8: 1267
   Google Scholar
• Kaplan M M. Medical approaches to primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 56–63
   PubMedGoogle Scholar
• Kaplan M M, Arora S, Pincus S H. Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Ann Intern Med 1987; 106: 231–5
   PubMed Web of Science ®Google Scholar
• Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial. Hepatology 1992; 16: 707–14
   PubMed Web of Science ®Google Scholar
• Wiesner R H, Grambsch P M, Dickson E R, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430–6
   PubMed Web of Science ®Google Scholar
• Lebovics E, Salama M, Elhosseiny A, Rosenthal W S. Resolution of radiographic abnormalities with ursodeoxycholic acid therapy of primary sclerosing cholangitis. Gastroenterology 1992; 102: 2143–7
   PubMed Web of Science ®Google Scholar
• Roy C C, Weber A M, Morin C L, et al. Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J Pediatr Gastroenterol Nutr 1982; 1: 469–78
   PubMed Web of Science ®Google Scholar
• Gaskin K J, Waters D LM, Howman-Giles R, et al. Liver disease and common bile duct stenosis in cystic fibrosis. N Engl J Med 1988; 318: 340–6
   PubMed Web of Science ®Google Scholar
• Bittner P, Posselt H G, Sailer T, . The effect of treatment with ursodeoxycholic acid in cystic fibrosis and hepatopathy: results of a placebo-controlled study. Bile acids as therapeutic agents, G Paumgartner, A Stiehl, W Gerok, et al. Kluwer Academic, Dordrecht 1991; 345–8
   Google Scholar
• Colombo C, Setchell K DR, Podda M, et al. Ursodeoxycholic acid (UDCA) Therapy in patients with cystic fibrosis (CF) and liver disease:P a dose-response study. Gastroenterology 1991; 100: A731
   PubMedGoogle Scholar
• Colombo C, Castellani M R, Balistreri W F, et al. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992; 15: 677–84
   PubMed Web of Science ®Google Scholar
• Birchner J. Treatment of patients with benign recurrent intrahepatic cholestasis. Hepatology 1989; 10: 1030
   PubMedGoogle Scholar
• Crosignani A, Podda M, Bertolini E, et al. Failure of ursodeoxycholic acid in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Hepatology 1991; 14: 1076–83
   PubMedGoogle Scholar
• Bijleveld C MA, Vonk R J, Kuipers F, et al. Benign recurrent intrahepatic cholestasis: a long-term follow-up study of two patients. Hepatology 1989; 9: 532–7
   PubMedGoogle Scholar
• Reyes H. The enigma of intrahepatic cholestasis of pregnancy: lessons from Chile. Hepatology 1982; 2: 87–96
   PubMed Web of Science ®Google Scholar
• Person H, Friman S, Schersten T, et al. Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients. Lancet 1990; 336: 52–3
   Google Scholar
• Böker K HW, Steinhoff G, Kohlhaw K, . Ursodeoxycholic acid for the treatment of anicteric cholestasis after liver transplantation. Bile acids as therapeutic agents, G Paumgartner, A Stiehl, W Gerok, et al. Kluwer Academic, Dordrecht 1991; 361–4
   Google Scholar
• Fried R H, Murakami C S, Fisher L D, et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992; 116: 624–9
   PubMed Web of Science ®Google Scholar
• Attili A F, Rusticali G, Carli L, et al. Effect of ursodeoxycholic acid (UDCA) on serum enzymes and liver histology in patients with chronic active hepatitis (CAH). Am J Gastroenterol 1991; 86: A133
   Google Scholar
• Yoshino K, Yamada H, Nishimura S, et al. Ursodeoxycholic acid (UDCA) therapy in liver cirrhosis. J Gastroenterol Hepatol 1992; S1: A81
   Google Scholar
• Setchell K DR. Disorders of bile acid synthesis. Pediatric gastrointestinal disease, W A Walker, P R Durie, J R Hamilton, J B Watkins. Decker, New York 1990; Vol. 2: 992–1012
   Google Scholar